Global Bulimia Nervosa Market Statistics Insights by Industry Size, Technology and Trend Analysis 2019 to 2023

The Global Bulimia Nervosa Market Statistics is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 429.84 million in 2018 and is projected to register a 4.9% CAGR over the forecast period.

Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems.

Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth.

The “Bulimia Nervosa Market Statistics” In-Depth competition analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.

The Bulimia Nervosa Market Statistics provide valuable insight with an emphasis on the global market including some of the major players such As, Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India)

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region. The competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled

Bulimia Nervosa Market Statistics Segment by Regions, regional analysis covers:

• North America(United States, Canada and Mexico)
• Europe(Germany, France, UK, Russia and Italy)
• Asia-Pacific(China, Japan, Korea, India and Southeast Asia)
• South America(Brazil, Argentina, Colombia etc.)
• Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/bulimia-nervosa-market-1417

The report also appraises the supervisory scenarios which affect various decisions in the market. With all the data congregated and scrutinized using SWOT analysis, there is a vibrant picture of the competitive scenario of the Global Bulimia Nervosa Market Statistics.

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com